Stockscreener 앱 받기
26.66
3.49%
0.90
전일 마감가:
$25.76
열려 있는:
$25.77
하루 거래량:
1.53M
Relative Volume:
1.04
시가총액:
$3.23B
수익:
$10.12M
순이익/손실:
$-280.49M
주가수익비율:
-9.2249
EPS:
-2.89
순현금흐름:
$-188.51M
1주 성능:
+10.58%
1개월 성능:
-21.19%
6개월 성능:
-45.05%
1년 성능:
+13.21%
1일 변동 폭
$25.66
$27.02
1주일 범위
$23.66
$27.67
52주 변동 폭
$21.51
$56.00
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
26.66 | 3.23B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Avidity Biosciences Plans First BLA Submission and Accelerates Commercialization Preparations for Three Rare Muscle Disease Programs in 2025 (PR Newswire) - Aktiellt
Beyond The Numbers: 13 Analysts Discuss Avidity Biosciences Stock - Benzinga
Japan grants Avidity’s DM1 drug Orphan status By Investing.com - Investing.com South Africa
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - StreetInsider
Avidity Biosciences Receives Orphan Drug Designation in Japan fo - GuruFocus
Avidity Says Japan Grants Orphan Drug Status to Del-Desiran for Myotonic Dystrophy Type 1 - marketscreener.com
Japan grants Avidity's DM1 drug Orphan status By Investing.com - Investing.com India
Japan grants Avidity's DM1 drug Orphan status - Investing.com
Avidity Biosciences Receives Orphan Drug Designation In Japan For Delpacibart Etedesiran - MarketScreener
Avidity Biosciences chief program officer sells shares worth $206,799 - MSN
Avidity Biosciences CFO sells $93,985 in stock - MSN
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - MSN
Avidity Biosciences’ chief program officer sells $163k in stock - Investing.com India
Avidity Biosciences’ chief program officer sells $163k in stock By Investing.com - Investing.com UK
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Nasdaq
When the Price of (RNA) Talks, People Listen - news.stocktradersdaily.com
Avidity Biosciences : to Present at the Virtual Chardan 4th Annual Genetic Medicines Conference 2020 - marketscreener.com
Avidity Biosciences to Participate in Upcoming Investor Conference - Quantisnow
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress - Investing.com India
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock - Investing.com Australia
Cantor Fitzgerald maintains $96 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Avidity Biosciences’s SWOT analysis: stock poised for growth amid clinical progress By Investing.com - Investing.com South Africa
Avidity Completes Enrollment in Del-brax Trial's Biomarker Group for Facioscapulohumeral Muscular Dystrophy - MarketScreener
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - StreetInsider
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy – Company AnnouncementFT.com - Financial Times
11 Best Gene Therapy Stocks to Buy According to Analysts - Insider Monkey
EFG Asset Management North America Corp. Purchases 58,198 Shares of Avidity Biosciences, Inc. (NASDAQ:RNA) - MarketBeat
The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (NASDAQ:RNA) - Seeking Alpha
Avidity Biosciences chief scientific officer sells $365,867 in stock By Investing.com - Investing.com Australia
Avidity Biosciences CFO Michael MacLean sells $246,424 in stock By Investing.com - Investing.com Australia
Avidity Biosciences Inc Stock: Leadership Sells Shares Amid Clinical Success - Sharewise
Avidity Biosciences chief HR officer sells $241,583 in stock By Investing.com - Investing.com Australia
Avidity Biosciences chief HR officer sells $241,583 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock - Investing.com India
Avidity Biosciences CEO Sarah Boyce sells $979,563 in stock By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $365,867 in stock - Investing.com
Avidity Biosciences chief medical officer sells $297,490 in stock - Investing.com
Avidity Biosciences Executives Sell Shares for Tax Obligations - TradingView
Avidity Biosciences Executives Sell Shares to Cover Tax Obligations - TradingView
Avidity Biosciences announces inducement grants under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Kilgore News Herald
H.C. Wainwright maintains $72 target on Avidity Biosciences stock By Investing.com - Investing.com Canada
Forecasting The Future: 13 Analyst Projections For Avidity Biosciences - Benzinga
Avidity’s del-zota elicits 25% increase in dystrophin in DMD patients - Yahoo Finance
New Duchenne Results Put Avidity On Course For Filing - insights.citeline.com
Avidity Biosciences reports progress in DMD treatment trial By Investing.com - Investing.com Australia
Avidity eyes 2025 BLA on back of positive DMD data - BioWorld Online
Avidity Biosciences Touts Positive Data From Early-Stage Duchenne Muscular Dystrophy Study Data, FDA Submission Expected By End Of 2025 - Benzinga India
Avidity Biosciences Shares Tumble Despite Trial Success - TipRanks
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
어비디티 바이오사이언스 주식 (RNA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Gallagher Kathleen P. | Chief Program Officer |
Apr 01 '25 |
Sale |
27.83 |
5,875 |
163,486 |
50,554 |
| Hughes Steven George | Chief Medical Officer |
Mar 20 '25 |
Sale |
31.06 |
9,578 |
297,491 |
72,850 |
| Boyce Sarah | President and CEO |
Mar 20 '25 |
Sale |
31.06 |
31,540 |
979,563 |
305,871 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 20 '25 |
Sale |
31.06 |
11,780 |
365,868 |
80,195 |
| MacLean Michael F | Chief Financial Officer |
Mar 20 '25 |
Sale |
31.06 |
7,935 |
246,425 |
96,720 |
| McCarthy Teresa | Chief Human Resources Officer |
Mar 20 '25 |
Sale |
31.06 |
7,778 |
241,583 |
97,130 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Option Exercise |
14.22 |
20,000 |
284,400 |
111,975 |
| Flanagan W. Michael | Chief Scientific Officer |
Mar 11 '25 |
Sale |
30.13 |
20,000 |
602,614 |
91,975 |
2.51%
자본화:
|
볼륨(24시간):